Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Peter Clark, MA, MD, FRCP: A Payer Perspective

Welcome and Introduction to Vi3C

Opportunities to Optimize Cancer Policies Panel Discussion

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

May

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Welcome and Introduction to Vi3C

Opportunities to Optimize Cancer Policies Panel Discussion

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Advanced CKM Syndrome Associated With Greater Cancer Risk

Integrated Molecular Analysis Identifies Determinants of Outcomes in TP53-Mutated DLBCL

Adjuvant Hepatic Arterial Infusion After Surgery for Four or More Colorectal Liver Metastases

Targeted Therapies Drive Long-Term Decline in Multiple Myeloma Mortality in the United States

AI Shows Dermatologist-Level Accuracy in Melanoma Diagnosis but Needs Validation